| |
Histopathological types of RCT
|
|---|
| |
ccRCC
|
pRCC I
|
pRCC II
|
chRCC
|
RO
|
CDC
|
MLCRN-LMP
|
Total N (%)
|
|
N (%)
|
120 (57.7)
|
7 (3.4)
|
16 (7.7)
|
28 (13.5)
|
25 (11.0)
|
7 (3.4)
|
5 (2.4)
|
208 (100)
|
|
Age, mean ± SD (years)
|
61.6 ± 9.05
|
70.4 ± 11.01
|
62.6 ± 10.8
|
58.3 ± 13.2
|
58.5 ± 12.5
|
52.7 ± 10.7
|
51.8 ± 15.9
|
60.7 ± 10.7
|
|
Gender N (%)
|
|
Male
|
79 (65.8)
|
6 (85.7)
|
10 (62.5)
|
15 (53.6)
|
12 (48.0)
|
6 (85.7)
|
4 (80.0)
|
132 (63.5) (64.4)
|
|
Female
|
41 (34.2)
|
1 (14.3)
|
6 (37.5)
|
13 (46.4)
|
10 (40.0)
|
1 (14.3)
|
1 (20.0)
|
73 (35.1)
|
|
Tumor size, mean ± SD (mm)
|
69.9 ± 43.8
|
78.3 ± 46.3
|
74.8 ± 22.7
|
65.4 ± 28.8
|
54.2 ± 29.5
|
66.4 ± 29.7
|
49.2 ± 12.1
|
68 ± 38.2
|
|
Grade N (%)
|
|
I
|
21 (17.5)
|
2 (28.6)
|
0 (0)
|
N/A
|
N/A
|
N/A
|
N/A
|
31 (18.2)
|
|
II
|
68 (56.7)
|
5 (71.4)
|
8 (50.0)
|
97 (56.7)
|
|
III
|
18 (15.0)
|
0 (0)
|
4 (25.0)
|
25 (14.6)
|
|
IV
|
13 (10.8)
|
0 (0)
|
4 (25.0)
|
18 (10.5)
|
|
Stage N (%)
|
|
pT1
|
58 (48.3)
|
4 (57.1)
|
5 (31.3)
|
13 (46.4)
|
N/A
|
N/A
|
N/A
|
80 (39.4)
|
|
pT2
|
13 (10.8)
|
1 (14.3)
|
3 (18.8)
|
3 (10.7)
|
20 (9.6)
|
|
pT3
|
38 (31.7)
|
2 (28.6)
|
7 (43.8)
|
10 (35.7)
|
57 (29.3)
|
|
pT4
|
11 (9.2)
|
0 (0)
|
1 (6.3)
|
2 (7.1)
|
14 (7.7)
|
|
PN
|
15 (12.5)
|
2 (28.6)
|
3 (18.6)
|
4 (14.3)
|
4 (36.4)
|
0 (0)
|
2 (40.0)
|
30 (14.4)
|
|
Follow up, mean months
|
41.7
|
50.3
|
41.9
|
49.3
|
54.4
|
36.1
|
74.8
|
44.2
|
|
Disease related death N (%)
|
39 (81.2)
|
0 (0.0)
|
5 (10.4)
|
2 (4.1)
|
0 (0)
|
2 (4.1)
|
0 (0)
|
48 (98.0)
|
- Abbreviations: RCT, Renal cell tumors; ccRCC,clear cell renal cell carcinomas; pRCC I,papillary renal cell carcinoma type I; pRCC II, papillary renal cell carcinoma type II; chRCC, chromophobe renal cell carcinoma; RO, renal oncocytoma; CDC,collecting duct carcinoma-Bellini; MLCRN-LMP, multilocular cystic renal neoplasm of low malignant potential; N, number; SD, standard deviation; N/A, not applicable; ISUP (International Society of Urological Pathology) nuclear grading system and updated American Joint Committee on Cancer (AJCC) tumor–node–metastasis (TNM) classification 8th edition for tumor staging were used
